
The allotment process for Sudeep Pharma IPO is expected to be finalised today on November 26, 2025. The shares of Sudeep Pharma Ltd will be listed on both NSE and BSE with a tentative listing date of November 28, 2025. The Company opened its Initial Public Offering on November 21, 2025, with an issue size of ₹895 crore.
Sudeep Pharma Ltd is a manufacturer of excipients and speciality ingredients for the pharmaceutical, food, and nutrition industries. The company supplies its products to domestic and international markets across various regions, including the United States (US), Europe, South America, the Middle East, Africa, and Asia-Pacific.
Sudeep Pharma's IPO was a bookbuilding issue, which consisted of a fresh issue of 0.16 crore shares aggregating to ₹95 crores and an offer for sale (OFS) of 1.35 crore shares aggregating to ₹800 crores. The IPO price band was set at ₹563-₹593 per share. The lot size for an application was 25, and the minimum amount of investment required by a retail investor was ₹14,825 (25 shares) based on the upper price.
[November 25, 2025, 6:20 PM]
On Day 3 of subscription, Sudeep Pharma Ltd saw an overall subscription of 93.715 times as per the NSE data on November 25, 2025, 6:20 p.m. The public issue was subscribed 15.65 times in the Retail Individual Investors (RIIs) category, 116.72 times in the Non Institutional Investors (NII) category and 213.08 times in the Qualified Institutional Buyers (QIBs) category.
Explore other Upcoming IPOs on BSE and NSE.
The Company will utilise the net proceeds from the fresh issue for the following purposes:
Check out newly Listed IPOs on BSE and NSE.
Sudeep Pharma Limited, incorporated in December 1989 and headquartered at Vadodara, Gujarat, is a manufacturer of mineral-based excipients and speciality ingredients serving the pharmaceutical, food and nutrition industries. The company’s product range includes calcium, magnesium, iron, zinc, potassium and sodium derivatives used as functional ingredients and excipients.
It operates manufacturing facilities in Vadodara (Gujarat) and exports to a vast global base. For the fiscal year ended December 31, 2024, Sudeep Pharma reported revenue from operations of about ₹ 344.45 crore and a net profit of approximately ₹ 94.54 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.